Molecure reports continued pipeline momentum for 6 months ended 30th June 2022

Our new name "Molecure" reflects expansion of scope of small molecule targets from novel proteins to mRNA in discovery & development of breakthrough therapies for multiple diseases Worldwide rights regained to novel, dual chitinase inhibitor OATD-01 following a strategic review by...